COMMUNIQUÉS West-GlobeNewswire

Spectral AI Raises up to $15 Million of Debt Financing and Strengthens Financial Position for U.S. Commercialization
24/03/2025
DALLAS, March 24, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to [...]
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
24/03/2025
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that [...]
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
24/03/2025
-- Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in oncology -- MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: [...]
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
24/03/2025
HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, [...]
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
24/03/2025
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary [...]
NativePath Native Hydrate: The Senior Hydration Solution That Supports Energy, Bladder Health & Brain Function
24/03/2025
MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Maintaining proper hydration is more crucial than ever in today's fast-paced world, especially for individuals over 60. Dehydration can lead to a host of health issues, [...]
TOMI Secures $450,000 Contract for Custom Engineered System (CES) Installation
24/03/2025
FREDERICK, Md., March 24, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced a significant [...]
Philips convenes the Annual General Meeting of Shareholders 2025
24/03/2025
March 24, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced it has convened the Annual General Meeting of Shareholders (AGM) 2025 and published the agenda with explanatory notes. As [...]
Abivax Announces Full Year 2024 Financial Results
24/03/2025
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely [...]
Press Release: Availability of the Q1 2025 Aide mémoire
24/03/2025
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025 . Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi. [...]
Communiqué de presse : Mise en ligne du document « Q1 2025 Aide mémoire »
24/03/2025
Mise en ligne du document « Q1 2025 Aide mémoire » Paris, France, le 24 mars 2025 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q1 2025 Aide [...]
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
24/03/2025
Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the [...]
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de BLA du patch Viaskin® Peanut chez les enfants de 4-7 ans, accélérant ainsi au premier semestre 2026 le dépôt de la demande…
24/03/2025
Châtillon, France, le 24 mars (7h30 CEST) 2024 DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de licence de produit biologique (BLA) du patch Viaskin® Peanut chez les [...]
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
24/03/2025
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to [...]
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
24/03/2025
Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of [...]
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
24/03/2025
Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in [...]
Valneva répond à l'appel du gouvernement français pour la fourniture du vaccin IXCHIQ® contre l'épidémie de chikungunya à La Réunion
24/03/2025
Saint Herblain (France), le 24 mars 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’elle répondait avec son vaccin IXCHIQ ® à l’épidémie de [...]
Opthea Announces COAST Phase 3 Trial Topline Results
24/03/2025
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a [...]
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
24/03/2025
SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]

Pages